The largest group of breast cancer patients are estrogen receptor-positive (ER+). There a vast amount studies focused on cancer. That vastness provides the requisites for integration and meta-analysis related studies. Meta-analysis could lead to more reliable results than single investigations, which in turn individually influenced by different known unknown batch effects. In present study, spe...

Increasing evidence supports an association between exposure to endocrine disruptors, such as the xenoestrogen bisphenol A (BPA), a commonly used plasticiser, and the developmental programming of offspring health. To date however animal studies to investigate a direct causal have mainly focussed on supra-environmental BPA concentrations, without investigating the effect on the early embryo. In ...

Endocrine therapy has been highly effective for the treatment of estrogen receptor-positive breast cancer, but endocrine resistance develops in a significant proportion of patients. In an effort to develop novel therapeutic strategies for the treatment of endocrine-resistant breast cancer, we have evaluated a potent and specific MDM2-p53 interaction inhibitor, MI-77301, which has been advanced ...

BACKGROUND Everolimus, an inhibitor of the mammalian target of rapamycin, shows promising antitumor activity when combined with trastuzumab and chemotherapy for human epidermal growth factor receptor-2 (HER2)-positive breast cancer or when combined with endocrine agents for hormone receptor (HR)-positive tumors. However, data are limited regarding the effect of everolimus in combination with en...

Authors' A Departmen Washingto Pathophy Shanghai, Note: Sup Cancer The Correspon Cancer Ce Road North 20057. Ph georgetown